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OBJECTIVES This study was designed to document the association of endocardial fibroelastosis (EFE) and
maternal autoantibodies.
BACKGROUND Neonatal lupus erythematosus is associated with the transplacental passage of maternal
anti-Ro and anti-La antibodies, leading to complete atrioventricular block (CAVB). In some
cases, CAVB is associated with EFE. Isolated EFE may be independently related to maternal
anti-Ro and anti-La antibodies.
METHODS We identified three cases (one fetus and two infants, all female) of isolated EFE in infants
born to autoantibody-positive mothers in the absence of CAVB. Demographics, echocar-
diograms, and pathology were reviewed. Immunohistochemical analyses for immunoglobulin
(Ig)G, IgM, IgA, T-cell, B-cell, and terminal deoxynucleoleotidyl transferase-mediated
dUTP-biotin nick end-labeling (TUNEL) (test for cell apoptosis) staining were performed
on multiple sections of the heart in each case and compared with negative controls.
RESULTS Two cases died and one received a cardiac transplant. All three cases had histologically
confirmed EFE. All cases demonstrated significant diffuse IgG infiltration. To a lesser extent,
myocardial tissue was also positive for IgM, CD43, and Granzyme B. None of the specimens
were TUNEL positive.
CONCLUSIONS These are the first reported cases of isolated EFE associated with maternal anti-Ro and
anti-La antibodies in the absence of CAVB. The diffuse deposition of IgG and the presence
of a T-cell infiltrate throughout the myocardium suggest that the transplacental passage of
maternal autoantibodies induces an immune reaction within the myocardium, leading to
isolated EFE. Autoantibody-mediated EFE may be an etiologic factor in cases of fetal and
neonatal “idiopathic” dilated cardiomyopathy. (J Am Coll Cardiol 2002;40:796–802)
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Neonatal lupus erythematosus (NLE) is an illness of the
fetus and neonate associated with the transplacental passage
of maternal anti-Ro and anti-La antibodies (1). The most
significant disease manifestations are related to cardiac involve-
ment, including complete congenital atrioventricular block
(CAVB) and first- and second-degree atrioventricular block.
When CAVB is associated with endocardial fibroelastosis
(EFE), there is a very high mortality rate (2). The link between
maternal autoantibodies and CAVB was originally suggested
from a single case report published in 1966 (3).
Endocardial fibroelastosis is a rare and poorly understood
disease of the endomyocardium that often progresses to
end-stage heart failure and death. Patients present in the
fetal or infant period with the clinical signs of congestive
heart failure (CHF) (4–6). The etiology of EFE remains
unclear, but it may be the result of an autoimmune process
(7). Endocardial fibroelastosis has been described in isolated
cases of CAVB (8–10) and has been attributed to long-
standing CAVB and bradycardia, leading to progressive
CHF (3). This hypothesis does not explain the finding that
not all patients with CAVB develop EFE. Furthermore,
some patients with anti-Ro and anti-La antibody-associated
CAVB have developed EFE despite adequate pacing at phys-
iologic heart rates, implying that perhaps EFE and CAVB are
two separate disease manifestations of NLE (11).
We describe one fetal case and two infant cases with EFE
and cardiomyopathy with clinically normal conduction systems
conceived by mothers positive for anti-Ro and/or anti-La
antibodies. Immunohistochemical studies demonstrated for
the first time that the fetal immune system played a role in the
evolution of myocardial damage seen in these patients.
METHODS
Demographic data collected on the three patients were
obtained from hospital records at the Hospital for Sick
Children, Toronto, Canada. All available fetal and postnatal
echocardiograms were reviewed by two investigators
(L. E. N. and L. K. H.). Echocardiographic parameters
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examined included: the left ventricular (LV) ejection frac-
tion, severity of mitral regurgitation, measurements of the
LV end-diastolic and posterior wall, interventricular septal,
right ventricular (RV) end-diastolic dimensions from
M-mode tracings, or two-dimensional images in centime-
ters. The presence or absence of endocardial fibrosis was
identified as areas of echogenicity on the endocardial surface
of the heart. The echogenicity was defined as bright,
white-appearing endocardium with clearly defined margins
and was graded as mild, moderate, or severe, depending on
the thickness and extent of myocardial involvement.
Pathology. The fetal and postnatal pathology reports and
slides from either autopsy specimens or explanted hearts
following cardiac transplantation were reviewed by one of two
pathologists who were blind to clinical data (G. P. T. and
J. B. M. M.) for: weight and shape of heart; severity of
endocardial fibrosis graded as mild, moderate, or severe; extent
of EFE defined as diffuse or focal; thickness of EFE defined as
thin or thick; and depth of EFE measured in millimeters (7).
Immunohistochemical analysis. In all three cases, 5 m
formalin-fixed, paraffin-embedded tissue sections were
mounted on positively charged microscopic slides. Tissue
sections were then baked overnight at 60°C dewaxed in
xylene and hydrated to distilled water through decreasing
concentrations of alcohol. All immunohistochemical proce-
dures were performed on the Ventana Gen II auto-immuno
in-situ stainer (Ventana Medical Systems, Tucson, Arizo-
na), a closed system using the avidin biotin complex (ABC),
employing “DAB (3-3-Diaminobenzidine) Ventana De-
tection System,” as outlined by the manufacturer. Briefly,
tissue sections were incubated with biotinylated antibodies
against human IgG, IgM, IgA, CD20, CD43, CD4, CD8,
and Granzyme B. Following automated washings, the tissue
sections were incubated with the ABC detection system
which contains perioxidase labeled streptavidin and DAB
chromagen, substrate, and copper enhancer. Tissue sections
were treated for endogenous peroxidase and biotin and
counterstained with haematoxylin for nuclear detail. For the
IgG, IgM, IgA staining, rabbit polyclonal antihuman spe-
cific antibody was used (DAKO, Carpinteria, California).
Monoclonal mouse antihuman specific antibody was used
for CD20, CD43, and CD8 (DAKO), using mouse IgG1
kappa isotypes. Monoclonal mouse anti-human antibodies
were used against CD4 (NovoCastra, Newcastle upon
Tyne, UK) and Granzyme B (Serotec, Oxford, UK). The
omission of the primary antibody from the serial section was
used as the negative control.
Deoxyribonucleic acid damaged cells were detected by the
terminal deoxynucleoleotidyl transferase (TdT)-mediated
dUTP-biotin nick end-labelling (TUNEL) technique, on 5
m formalin-fixed, paraffin-embedded tissue sections (12).
This technique tests for the presence of apoptosis, or cell-
mediated death. The procedure was adapted to an automated
in situ hybridization instrument (GEN II, Ventana Medical
Systems, Inc.). All tissue sections were treated for endogenous
peroxidase with 3% hydrogen peroxide methanol solution and
endogenous biotin (Vector Avidin Biotin Blocking Kit, Vector
Laboratories, Inc., Burlingame, California). The protocol in-
volved Protease I (Ventana Medical Systems) enzyme diges-
tion for 8 min at 37°C of the TUNEL reaction mixture,
comprising of recombinant TdT in TdT buffer (Gibco BRL,
Gaithersburg, Maryland), for adding homo-polymer tails to
the 3 ends of deoxyribonucleic acid. Biotinylated-16-dUTP
(Boehringer Mannheim, Mannheim, Germany) was the label
used for terminal transferase in this reaction. Negative controls
were obtained by omitting the recombinant TdT. Colormetric
detection was performed using a mouse anti-biotin (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania)
at 37°C for 32 min followed by the DAB(3-3-
Diaminobenzidine) Ventana ABC Detection System. The
counterstain of preference was haematoxylin, for nuclear detail.
A 20-week gestation fetus, a one-month-old infant and a
six-month-old infant were used as negative case controls.
The 20-week fetus died secondary to therapeutic abortion, the
one-month-old was a sudden infant death syndrome related
death who had no evidence of infection and the six-month-old
died of asphyxia. All cases were stained for IgG, IgA, IgM,
CD20, CD43, CD8, Granzyme B, and TUNEL staining
using the identical methods outlined above.
All slides were reviewed by E. D. S. and L. E. N. who
were blinded to clinical data and compared with positive and
negative controls for both the fetal and postnatal specimens.
Each marker was recorded as either positive or negative. If
positive, the strength of the reaction was graded as,, and
, depending on the extent of infiltration (diffuse or focal)
and location (global, central, or peripheral).
Case presentations. CASE 1. This six-month-old female pre-
sented with a history of progressive tachypnea, diaphoresis and
poor oral intake over several months. She was born at term to
a 25-year-old G2P1 mother with systemic lupus erythemato-
sus. The mother was anti-Ro, but not anti-La, antibody
positive. The mother was treated with hydroxychloroquine
sulfate but did not receive corticosteroids during the pregnancy.
Because of her diagnosis of systemic lupus erythematosus, the
mother had had two screening fetal echocardiograms at 20 and
28 weeks gestation. Both studies showed an anatomically
normal heart with normal cardiac function and normal sinus
rhythm with occasional premature atrial contractions.
At presentation, the baby was diagnosed with severe CHF.
The echocardiogram at the time of admission revealed an
Abbreviations and Acronyms
CAVB  complete atrioventricular block
CHF  congestive heart failure
EFE  endocardial fibroelastosis
Ig  immunoglobulin
LV  left ventricular
NLE  neonatal lupus erythematosus
RV  right ventricular
TUNEL  terminal deoxynucleoleotidyl transferase-
mediated dUTP-biotin nick end-labeling
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anatomically normal heart with LV and RV dilation, severely
reduced ventricular function (ejection fraction 25% by
M-mode), and moderate mitral regurgitation. There were
areas of echogenicity consistent with EFE, predominately seen
in the left ventricle along the interventricular septum and the
mitral valve papillary muscles (Fig. 1). Medical management
failed the child and it was listed for cardiac transplantation. An
echocardiogram on the day before cardiac transplantation
revealed persistent LV dilation and ventricular dysfunction
(ejection fraction 27% by Simpson’s rule). The areas of in-
creased echogenicity were noted to be more severe when
compared with the initial study, and involved the interventric-
ular septum and free wall of the left ventricle and papillary
muscles of the mitral valve. The electrocardiogram showed
sinus rhythm (PR interval 0.08 ms) with a nonspecific intra-
ventricular conduction block at a rate of 120 beats/min. The
patient is currently alive, five years after cardiac transplantation.
CASE 2. This female fetus presented at 22 weeks gestation
with supraventricular tachycardia and hydrops fetalis. The
mother was a 31-year-old G5P3 healthy woman, known to be
positive for anti-La but negative for anti-Ro antibody. She had
a previous miscarriage at 22 weeks of a fetus with oligohy-
dramnios, which had prompted autoantibody screening for this
pregnancy. A fetal echocardiogram was performed during this
pregnancy to rule out supraventricular tachycardia suspected on
routine obstetrical ultrasound examination. The initial echo-
cardiogram at 22 weeks gestation revealed hydrops fetalis with
a structurally normal heart, moderate ascites, and severely
reduced ventricular function. The heart rate was predominately
in normal sinus rhythm at a rate of 140 to 195 beats/min with
occasional premature atrial contractions. The LV end-diastolic
and posterior wall dimensions were within normal limits,
whereas the right ventricular end-diastolic dimension was at
the upper limit of normal for gestational age (13). The
myocardium was echogenic, with predominant RV involve-
ment and mild LV wall echogenicity.
The mother was treated with oral digoxin and dexameth-
asone. The fetus was followed clinically and by echocardi-
ography. Follow-up studies at 25 weeks gestation revealed
severe fetal sinus bradycardia at a rate of 40 to 95 beats/min
with 1:1 atrioventricular conduction and severe bilateral
ventricular dysfunction. The right ventricle, left ventricle, and
LV free wall dimensions were at the upper limit of normal for
gestational age. The echogenicity of the right and left ventricles
was unchanged from the initial study and also involved both
the right and left atria. Both echocardiographic studies dem-
onstrated moderate tricuspid regurgitation, but no mitral re-
gurgitation. The fetus died in utero one week later.
CASE 3. This patient was a three-month-old, previously
healthy girl, who presented to a peripheral hospital emer-
gency department with a two-day history of vomiting. She
was noted to be in severe CHF with sinus tachycardia and
could not be resuscitated. She was transferred moribund to
the Hospital for Sick Children. There were no echocardio-
grams available for review. The mother was a 21-year-old
G3P3 healthy woman, found to be anti-Ro positive and
anti-La antibody negative as part of a research study (tested
four years after the child’s demise).
RESULTS
Pathologic findings. CASE 1. The explanted heart was
globular in shape, with severe EFE (Fig. 2), predominately
in the left ventricle, where it was diffuse and thick (1 mm
depth). There was evidence of focal mild EFE in the right
ventricle. The right and left atria were unaffected. There was
a nonobstructive mural thrombus in the LV outflow tract.
CASE 2. At postmortem, the heart had a normal shape and
weight. There was mild focal EFE affecting multiple areas
of the heart including the right atrium, LV outflow tract,
and mitral valve papillary muscles. The EFE was predom-
inately present in the left side of the heart, with a maximal
depth of 0.5 mm. The mitral valve papillary muscles were
dystrophic and calcified. The sinus node and atrioventricular
node were calcified. The right atrium was dilated.
CASE 3. The heart was globular in shape, with mild, diffuse
EFE. The EFE predominately involved the left ventricle at
a depth of 0.3 to 0.5 mm, but was also present in focal areas
in the right ventricle. The mitral valve papillary muscles
were not available for review. There was no EFE in either
the left or right atria. Of note, on histology there were five
mitotic figures with evidence of myocyte hyperplasia.
Immunohistochemical findings. CASE 1. Immunohisto-
chemical staining of LV tissue was strongly and diffusely
positive for immunoglobulin (Ig)G, moderately positive for
IgM and mildly positive for IgA deposition (Table 1).
Although less striking, the tissue also contained areas that
had an infiltrate of anti-CD43, anti-CD8 mononuclear
cells and areas that stained positive for Granzyme B. The
Figure 1. Transthoracic echocardiogram at the time of hospital admission
for congestive heart failure demonstrating a dilated left ventricle (LV) with
areas of endocardial fibroelastosis along the endocardial surface of the LV,
mitral valve, and papillary muscles. LA  left atrium.
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TUNEL staining was negative and we did not detect
anti-CD20 or anti-CD4 cells (Fig. 3).
CASE 2. Immunohistochemical staining was similar to case
1, with diffuse areas of IgG deposition and a milder degree
of IgM deposition in the myocardium (Table 1). However,
only right atrial and atrioventricular nodal tissue, not LV or
RV tissue, were available for analysis. In addition, there
were some areas that had foci of anti-CD20 cells and
others with foci of anti-CD43 cells. The TUNEL stain-
ing was negative, as was staining with other antibodies.
CASE 3. Immunologic staining of LV tissue showed strong,
diffuse areas with evidence of IgG and IgM but not IgA
deposition (Table 1). We did not detect any areas of
anti-CD20 cells. There were diffuse areas that contained
large numbers of anti-CD43 cells with some focal areas
showing an infiltrate with CD8 cells and evidence of
Granzyme B, but no evidence of CD4 cells. As with the
other two cases, TUNEL staining was negative.
Control cases. All immunohistochemical stains were neg-
ative in the one-month and six-month-old infant hearts
tested. The 20-week fetal heart demonstrated diffuse stain-
ing with IgG but not IgM or IgA, as seen in the cases. The
intensity of the IgG staining was less than that generally
seen in the three cases (Fig. 4). Staining for CD20, CD43,
CD8, and Granzyme B were all negative.
DISCUSSION
Neonatal lupus erythematosus represents a spectrum of
disease involving the heart, skin, and liver in patients born
to anti-Ro and anti-La antibody-positive mothers (1). The
most common cardiac manifestation is isolated CAVB.
Although CAVB may be associated with the development
of EFE (2), to our knowledge, the cases reported here are
the first cases of isolated EFE associated with maternal
anti-Ro and anti-La antibodies in the absence of CAVB.
All three of our cases presented with severe congestive heart
failure or fetal hydrops, resulting in death in two patients
and cardiac transplantation in one patient. Given that
myocarditis in infants with NLE has been described (1), we
suggest that our cases illustrate that EFE may be the most
severe consequence of fetal or neonatal lupus myocarditis, and
may, in fact, be a separate cardiac manifestation of NLE.
Maternal anti-Ro and anti-La antibodies are known to
Figure 2. Pathologic specimen of the explanted heart illustrating diffuse,
severe endocardial fibroelastosis in the left ventricle, mitral valve and
papillary muscles, and the globular-shaped heart.
Table 1. Immunologic Data
Case No.
Specimen
Type IgA IgM IgG CD 20 CD 43 CD 4 CD 8 Granzyme TUNEL
1 LV    –  –   –
P D D P F
LV    –  – –  –
P D D F
2 Liver * *  * *
AV node     – –
F F
RA      –
F F F
3 LV –   –  –   –
D D D F
LV –   –     –
D D D F
*Within normal limits for tissue.
AV  atrioventricular; CD 4  helper T-cell marker; CD 8  killer T-cell marker; CD 20  pan B-cell marker; CD 43 
pan T-cell marker; D  diffuse; F  focal; Granzyme B  activated CD 8 cell marker; LV  left ventricle; P  peripheral;
RA  right atrium; TUNEL  staining for apoptosis.
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cross the transplacental barrier in utero, deposit in the
myocardium, and result in inflammation, fibrosis, and ulti-
mately irreversible myocardial damage (14–18). In addition
to the effect these antibodies have on the atrioventricular
node, they can also deposit directly onto fetal myocardium,
leading to myocardial fibrosis (19,20). In most cases, the
transplacental passage of maternal autoantibodies leads to
damage to the conduction system of the heart, with or without
an associated EFE. Endocardial fibroelastosis, a specific form
of myocardial fibrosis, consists of collagen and elastin hyper-
plasia and diffuse endocardial thickening (21). Our small series
suggests that there exists a subgroup of fetuses and infants in
whom maternal autoantibodies may damage the developing
myocardium, resulting in EFE without concomitant CAVB.
Figure 3. Paraffin sections of case 1 using alkaline phosphatase-conjugated antibodies directed against (staining methods as outlined in Methods section):
(A) human immunoglobulin (Ig)G demonstrating diffuse deposition of IgG; (B) human IgM demonstrating focal areas of deposition; (C) negative terminal
deoxynucleoleotidyl transferase-mediated dUTP-biotin nick end-labeling staining for apoptosis; (D) negative staining for pan B cell marker (CD 20); (E)
focal areas of pan T cell marker (CD 43); and (F) focal area of Granzyme B positive staining (magnification 25  10  1.25).
Figure 4. Paraffin sections of case 1 and normal control case using alkaline phosphatase conjugated antibodies directed against (staining methods as outlined
in Methods section): (A) human immunoglobulin (Ig)G demonstrating dense, diffuse deposition of IgG with loss of nuclei and myocardial disarray; (B)
human IgM demonstrating focal areas of deposition; (C) human IgG in control case demonstrating mild, diffuse IgG deposition with a normal myocardial
muscle pattern with normal, multiple nuclei; (D) human IgM in control case showing normal myocardial muscle pattern with normal, multiple without
deposition of IgM (magnification 20  0.5).
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We confirmed that there was diffuse deposition of IgG
throughout the myocardium of all three cases. Previous
investigators have been able to demonstrate IgG, anti-Ro,
and anti-La antibodies on the hearts of fetuses who died of
CAVB (15,17,19,22). Taken together, these findings sug-
gest that anti-Ro and anti-La antibodies deposit throughout
the myocardium, and not just within the conduction system.
More importantly, we demonstrate for the first time that
there is IgM and occasionally IgA deposition, a T-cell and,
to a lesser degree, a B-cell myocardial infiltrate. The finding
of IgM and the occasional B-cell in fetal cardiac tissue
suggests that there is an active fetal B-cell response in
addition to the passive deposition of transplacentally passed
maternal immunoglobulin. Furthermore, the presence of a
T-cell infiltrate in the myocardium, and in particular CD8
cells and their effector molecules Granzyme B (as evidence
of T-cell activation) also support the likelihood of a true
autoimmune reaction mounted by the fetus. Although it is
possible that the T-cells are of maternal origin, it is very
unlikely. Maternal T-cells are found relatively infrequently
in the fetus, and can only be detected using the polymerase
chain reaction technique (23,24). Finally, we excluded pro-
grammed cell death or apoptosis as a mechanism of develop-
ment of the myocardial pathology. The fetal and neonatal
autoimmune reaction in response to the maternal autoantibody
deposition may explain the observed progression of EFE
throughout fetal life and early infancy. Therefore, we suggest
that, although the initial myocardial damage in utero is likely
secondary to the passive deposition of maternal anti-Ro and
anti-La antibodies, the progression of EFE may be the result
of an ongoing fetal and postnatal autoimmune reaction.
Incidence of EFE. The true incidence of maternal
autoantibody-induced EFE is unclear. We identified a total
of three cases of EFE with normal conduction systems at
the Hospital for Sick Children. During that same time
period (1981 to 2001), we have found 11% of 46 patients
with autoantibody-induced CAVB to have clinically signif-
icant and echocardiographically detectable EFE (2). Al-
though this incidence is relatively low, the EFE accounted
for over 80% of the deaths in these patients. As nearly half
of the deaths associated with EFE occurred before birth, it
is likely that some cases of autoantibody-mediated EFE
with or without conduction disturbances may go undiag-
nosed where there is fetal demise. In addition, a less severe
spectrum of the disease may go unrecognized. In our
experience, echocardiographic assessment is very subjective
and often identifies only the most severe degree of EFE.
Finally, on the basis of our observations in the present study,
there is likely a subgroup of “idiopathic” dilated cardiomy-
opathies identified prenatally and postnatally that represent
unrecognized maternal autoantibody-induced EFE. Given
that at least 70% of mothers with anti-Ro and anti-La
antibodies with affected offspring are clinically asymptom-
atic (that is, no autoimmune disease), screening mothers, and
perhaps the affected fetus or infant, for autoantibodies would
be the only method of identifying such cases (25,26). Still, the
majority of patients with autoantibody-induced CAVB do not
develop severe and clinically manifested EFE and, from the
present case series, there are other patients that develop only
EFE without clinically manifested conduction abnormalities.
Anti-Ro and anti-La antibodies are present in at least
0.1% to 0.2% of the general population (27,28), yet CAVB
occurs in 1/14,000 live births (29). As well, CAVB occurs
only in 1% to 6% of pregnancies with anti-Ro and anti-La
antibodies (30,31), suggesting further that there must be
additional maternal and/or fetal factors that influence dis-
ease development and manifestation. The maternal factors
may be related to the autoantibody profile of mothers of
children with NLE, which differs from that of mothers with
connective tissue disorders and unaffected children (32–34).
We and others have also found that certain peptides derived
from the La and Ro proteins to be recognized by sera from
mothers with affected children, but not from mothers of
unaffected children (32–34). The development of severe
EFE may require a secondary “trigger” such as viral infec-
tion or genetic predisposition, leading to a more global
inflammatory reaction within the myocardium. Finally, the
responsiveness of the fetal immune system may also con-
tribute to autoantibody-mediated cardiac disease develop-
ment and severity. We suggest that CAVB may be second-
ary to differences in maternal autoantibody repertoire and
offspring susceptibility or predisposition.
Clinical implications. Irrespective of its true etiology and
epidemiology, recognition of maternal autoantibody-
induced EFE may be important for the clinical management
of the affected child. Immunosuppressive agents such as
corticosteroids, intravenous gamma globulin, and plasma-
pheresis may improve the outcome of these patients. Both
prenatal maternal and postnatal infant corticosteroid therapy in
the context of autoantibody-induced CAVB with cardiomy-
opathy have been shown to improve ventricular function in
some cases (35–37). In addition, anti-inflammatory agents
have been used in the management of children and adults
diagnosed with acute myocarditis with some success (38,39).
Given that the current management of EFE and CHF is
essentially limited to supportive care and antifailure medica-
tions, the use of anti-inflammatory agents might have a
tremendous impact on the clinical outcome of these patients.
Recognition of maternal autoantibodies as a cause of
isolated EFE and cardiomyopathy also has important im-
plications for the mother and offspring. We and others have
shown that many mothers who are asymptomatic at the
time of diagnosis of NLE in their child will develop clinical
signs and symptoms later in life (40). In addition, the
presence of maternal autoantibodies places subsequent off-
spring at risk of NLE, and therefore future pregnancies
should be followed closely for the development of CAVB,
EFE, or other manifestations of NLE.
CONCLUSIONS
In this paper we have reported for the first time the
association of isolated EFE in the absence of CAVB and
maternal autoantibodies. We have demonstrated that there
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is likely a fetal autoimmune component to NLE, as sug-
gested by the presence of a T-cell infiltrate and IgM
deposition. Further studies are necessary to determine the
true incidence of autoantibody-induced EFE in fetal and
infant cases of idiopathic dilated cardiomyopathy and to
determine if other manifestations of NLE may have an
autoimmune component. We are currently prospectively mea-
suring anti-Ro and anti-La antibodies in infants under 12
months of age presenting with dilated cardiomyopathy or
myocarditis, and in their mothers, to determine the incidence
of anti-Ro/anti-La antibody associated cardiomyopathy.
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